Govt Enforces ‘Melt and Pour’ Rule for All Steel in Public Projects Nippon Steel expected to finalize U.S. Steel acquisition at $55 per share NMDC Limited reports a 38% drop in Q4 FY24 consolidated net profit RINL to Raise $23 Million Through Land Sales Amid Crisis
The Competition Commission of India (CCI) declared that it has approved a proposal to acquire a 100% stake in Coastal Energen Pvt Ltd by Adani Power Ltd and Dickey Alternative Investment Trust. Adani Power Ltd (APL), a part of the diversified Adani Group, is the top private-sector thermal power producer in India.
The proposed transaction involves the acquisition of 100% equity share capital of Coastal Energen Pvt Ltd (CEPL) by the acquirers (Dickey Alternative Investment Trust (DAIT) and APL), according to a release by fair trade regulator CCI. DAIT is a Sebi-registered Alternative Investment Fund (AIF). It is acting through its investment manager Dickey Asset Management Pvt Ltd.
CEPL is engaged in the business of generation and sale of power. The company is undergoing a Corporate Insolvency Resolution Process (CIRP) under the insolvency and bankruptcy code. In another release, CCI granted its approval to Matrix Pharma Pvt Ltd's proposal to acquire 100% shareholding of Tianish Laboratories Pvt Ltd.
Tianish Laboratories carries out the business of manufacture and sale of active pharmaceutical ingredients in India. The acquirer (Matrix Pharma) proposes to purchase 100% of the equity shares of the target (Tianish Laboratories), the release said. Prior to Matrix Pharma's acquisition, the Investors (Kotak Strategic Situations India Fund II and Kotak Alternate Asset Managers) propose to subscribe to certain optionally convertible debentures of the Matrix Pharma Pvt Ltd.
The proceeds of this investment will be utilised by the Matrix Pharma towards its acquisition of Tianish Laboratories. Kotak Strategic Situations India Fund II is a Sebi-registered AIF, while Kotak Alternate Asset Managers acts as an investment manager, engaged in the business of managing and advising funds. Matrix Pharma does not presently carry out any business activity either in India or outside India. The deals beyond a certain threshold require approval from the regulator, which keeps a tab on unfair business practices and promotes fair competition in the marketplace.
Also Read : GAIL's Q3 net profit soars 703%, approves ₹5 dividend; inks long-term LNG deal with Vitol JSW Steel USA collaborates with Primetals Technologies for Ohio plant upgrade
Trump Gains Oversight Role in Nippon Steel’s $15 Billion U.S. Steel Acquisition Nippon Steel...
Announcement 27-Jun-2025
Jindal Steel & Power reported a consolidated net profit of ₹1,928 crore for the third quarter of...
Large Corporate 31-Jan-2024
TotalEnergies has signed a sale and purchase agreement (SPA) with Sembcorp Fuels, a wholly owned sub...
Europe 29-Feb-2024
Adani Enterprises, India's conglomerate, reported a substantial increase in its third-quarter profit...
Large Corporate 01-Feb-2024
Germany's proposed low-emission steel standard could create significant challenges for the Indian st...
Business 09-Aug-2024
Coal India Limited has set a target of producing 838 million tonnes (MT) of coal in fiscal year 2024...
Mid Corporate 26-Feb-2024